In patients with HER2+ BC and residual disease, no optimal cut-off values for relative change of Ki-67 expression were identified based on the available data, indicating the lack of prognostic value for Ki-67 expression dynamics in this biological setting. This evidence concerns the gene ERBB2 and breast cancer.